India’s private healthcare sector is generating some of the most closely watched IPO filings of 2026, as hospital operators with growing bed capacity and improving financials seek public market capital to retire debt and accelerate expansion. The Paras Healthcare IPO opens on October 21, 2026, and brings an eight-hospital, 2,211-bed tertiary and quaternary care network to the mainboard for the first time. The company operates under the Paras Health brand across tier 2 and tier 3 cities in North India, Bihar, and Jharkhand, a geography that mainstream hospital chains have underserved. The issue size is Rs 1,450 crore, split between a Rs 500 crore fresh issue and a Rs 950 crore OFS, with proceeds from the fresh component earmarked primarily for debt repayment. With GMP at Rs 95 as of October 16 and listing scheduled for October 28, the Paras Healthcare IPO 2026 deserves a closer look from retail investors before the window opens.
Paras Healthcare IPO at a Glance
| Parameter | Details |
|---|---|
| Company Name | Paras Healthcare Limited |
| Brand | Paras Health |
| IPO Open Date | October 21, 2026 |
| IPO Close Date | October 23, 2026 |
| Anchor Allotment Date | October 19, 2026 |
| Allotment Date | October 26, 2026 |
| Refund / Demat Credit | October 27, 2026 |
| Listing Date | October 28, 2026 |
| Exchange | BSE and NSE |
| Issue Type | Mainboard, Book-Built |
| Total Issue Size | Rs 1,450 crore (2,09,23,520 shares) |
| Fresh Issue | Rs 500 crore (72,15,007 shares) |
| OFS Component | Rs 950 crore (1,37,08,513 shares) |
| Price Band | Rs 660 to Rs 693 per share |
| Face Value | Rs 1 per share |
| Lot Size | 21 shares (Rs 14,553 minimum) |
| QIB Quota | 75% of net offer |
| NII Quota | 15% of net offer |
| Retail (RII) Quota | 10% of net offer |
| Registrar | MUFG Intime India Pvt. Ltd. |
| Lead Managers | JM Financial Ltd., BofA Securities India Ltd., Nuvama Wealth Management Ltd. |
| Paras Healthcare IPO GMP (Oct 16, 2026) | Rs 95 (+13.71%) |
| Estimated Listing Price | Rs 788 |
The date range, price band, and lot size above are confirmed from the Red Herring Prospectus. The allotment date is October 26, 2026, with refund and demat credit following on October 27.
What Is Paras Healthcare Limited?
Paras Healthcare Limited operates under the Paras Health brand and has built a clinical specialty-led hospital network focused on tertiary and quaternary care across North India, Bihar, and Jharkhand. The company was incorporated in 1987 and opened its first hospital in Gurugram in 2006. As of June 30, 2026, eight hospitals and 2,211 operational beds are active across Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi, and Srinagar. The Srinagar hospital operates through wholly-owned subsidiary PMHPL.
Six clinical specialties, branded internally as CONGOR, form the revenue core: Cardiac sciences, Oncology, Neurosciences, Gastro sciences, Orthopedics and sports injury, and Renal sciences. CONGOR contributed 75.30% of FY2026 revenue, anchoring the business in high-acuity procedures that carry better margins than routine care. The company serves primarily tier 2 and tier 3 cities where organised multi-specialty tertiary healthcare from private chains remains scarce.
As of March 31, 2026, the company employed 4,670 people, including 1,084 doctors and 1,937 nurses. Promoter Dr. Dharminder Kumar Nagar held 72.8% pre-IPO. Two expansion projects are in development: a 300-bed Gurugram facility and a 500-bed Ludhiana hospital, targeting a total of 3,011 beds by March 2028.
Past capital raises signal investor confidence. Commelina Ltd. invested Rs 260 crore in 2017. In 2025, 360 ONE Special Opportunities Fund added Rs 58.7 crore and Axis New Opportunities AIF added Rs 21.3 crore. Commelina Ltd. is now one of the OFS selling shareholders, exiting via a Rs 650 crore sale at the IPO price, a meaningful return on a nine-year holding.
Paras Healthcare IPO , Issue Structure and What It Means for Investors
The issue raises Rs 1,450 crore in total. The fresh issue of Rs 500 crore goes directly to the company for defined purposes. The OFS of Rs 950 crore goes entirely to selling shareholders: Rs 300 crore from promoter Dr. Dharminder Kumar Nagar and Rs 650 crore from Commelina Ltd.
The objects of the fresh issue break down as follows. Prepayment or repayment of company borrowings accounts for Rs 320.90 crore. Investment in subsidiary PMHPL for debt repayment accounts for Rs 54.10 crore. The remainder covers general corporate purposes. Combined, Rs 375 crore of the Rs 500 crore fresh issue goes toward defined debt reduction.
The high leverage context makes this use of proceeds significant. Total borrowings stood at Rs 1,393.86 crore as of March 31, 2026, producing a debt-to-equity ratio of 3.53x. Reducing borrowings by Rs 375 crore should lower annual finance costs and directly improve post-listing net margins, which is the bull case the IPO valuation is pricing in.
Retail investors should note that the OFS at Rs 950 crore represents 65% of total IPO proceeds. That capital goes to existing shareholders, not to the business. Commelina Ltd.’s Rs 650 crore OFS exit at Rs 693 per share on a Rs 260 crore 2017 investment represents a strong nine-year return for that institutional investor. The company’s capital comes only from the Rs 500 crore fresh component.
Check Upcoming IPOs in India 2026 for the full mainboard and SME listing calendar.
Paras Healthcare IPO GMP Today , What the Grey Market Is Signalling
The grey market premium stands at Rs 95 per share as of October 16, 2026. Added to the upper price band of Rs 693, this implies an estimated listing price of Rs 788, representing a notional gain of approximately 13.71%.
GMP Trend (Pre-Subscription, IPO Opens October 21)
| Date | GMP | Implied Gain |
|---|---|---|
| Oct 14, 2026 | Rs 83 | ~12.0% |
| Oct 15, 2026 | Rs 95 (intraday high Rs 120) | ~13.71% |
| Oct 16, 2026 | Rs 95 | ~13.71% |
The GMP reading is at an early stage. The grey market has only three sessions of data, all before subscription opens. The intraday swing from Rs 83 to Rs 120 on October 15 reflects thin trading rather than settled consensus. A more stable and reliable GMP reading will emerge once subscription opens on October 21 and institutional bids begin flowing. The current Rs 95 reading is pre-subscription sentiment, not a confirmed listing price signal.
The grey market premium is unofficial. No exchange publishes it. SEBI does not validate it. The actual listing price on October 28 will depend on Nifty direction, sector sentiment, subscription levels across all three categories, and institutional selling on Day 1. Treat it as one directional input among several, not as a guarantee.
Track live Paras Healthcare IPO GMP today alongside all active IPOs at IPO GMP Today.
Financials and the Turnaround Story , Reading the Numbers Honestly
The Paras Healthcare IPO review must start with the financial history, because it is not a straightforward growth story. The company posted net losses in both FY2024 (Rs 15.33 crore) and FY2025 (Rs 57.98 crore). FY2026 is the first profitable year, with PAT of Rs 43.83 crore. The company is listing one year into profitability. That context matters when evaluating the valuation multiples.
Financial Summary (Rs crore, Restated Consolidated)
| Particulars | FY2024 | FY2025 | FY2026 | Q1 FY2027 |
|---|---|---|---|---|
| Revenue from Operations | 1,129.04 | 1,294.06 | 1,605.95 | 478.75 |
| EBITDA | 154.41 | 156.46 | 335.58 | 113.48 |
| PAT | -15.33 | -57.98 | 43.83 | 49.68 |
| Total Borrowings | 923.92 | 1,232.12 | 1,393.86 | 1,429.49 |
Revenue grew from Rs 1,129 crore in FY2024 to Rs 1,606 crore in FY2026, a CAGR of approximately 19%. EBITDA expanded from Rs 154 crore to Rs 335 crore in the same period, with EBITDA margin reaching 20.60% in FY2026 and 23.70% in Q1 FY2027. The margin expansion is genuine and driven by operating leverage as utilisation rates improved across the hospital network.
The post-IPO valuation sits at 37.72x P/E using post-IPO EPS of Rs 18.37. The pre-IPO P/E on pre-IPO EPS of Rs 4.34 produces a figure of 159.68x, which reflects how recent the profit turn is. Market cap at the upper band: Rs 7,498.34 crore. P/B at 17.72x on FY2026 NAV. These multiples only hold if the turnaround sustains and accelerates.
Three financial risks deserve direct attention. Debt-to-equity of 3.53x remains high even after the fresh issue debt reduction. ROCE of 10.76% in FY2026 is improving but trails the levels typical for established listed hospital chains such as Apollo Hospitals or Max Healthcare. The profitability track record is one year old, and FY2027 and FY2028 performance remains unproven.
What the Q1 FY2027 Numbers Actually Say
Q1 FY2027 PAT of Rs 49.68 crore exceeds full-year FY2026 PAT of Rs 43.83 crore in a single quarter. Revenue for the quarter was Rs 478.75 crore, implying an annualised run rate above Rs 1,900 crore. EBITDA margin expanded to 23.70%, up from 20.60% in FY2026. If Q1 FY2027 performance carries through the full year, FY2027 PAT in the range of Rs 180 to Rs 200 crore becomes plausible, bringing the forward P/E to a level more defensible for a healthcare growth platform. The Q1 data is the most important input in the Paras Healthcare IPO review for any investor making a forward-looking assessment.
Mainboard vs SME IPO , What First-Time Applicants Must Know
First-time applicants sometimes confuse mainboard IPOs with SME board listings. The differences in minimum investment, disclosure standards, and post-listing liquidity are material.
| Feature | Mainboard IPO (Paras Healthcare) | SME IPO |
|---|---|---|
| Minimum Investment | Rs 14,553 (1 lot, 21 shares at Rs 693) | Rs 1,2 lakh or more |
| Listing Exchange | NSE and BSE main boards | NSE Emerge or BSE SME |
| SEBI Disclosure Norms | Full RHP mandatory | Lighter disclosures |
| Post-Listing Liquidity | Higher trading volumes | Thinner, more volatile |
| Allotment Basis | Lottery per PAN for retail | Lottery |
| QIB Allocation | 75% of net offer | 50% |
| Retail Quota | 10% of net offer | 35% |
| Eligibility | Any SEBI-registered broker app | Same |
A critical distinction for this specific issue: the Paras Healthcare IPO allocates only 10% of its net offer to retail investors, versus the 35% that most mainboard IPOs reserve for retail. At 10% retail allocation, even moderate oversubscription produces significantly tighter allotment odds per PAN than a standard mainboard issue. First-time applicants should factor this into their planning.
Read the full breakdown at Mainboard IPO vs SME IPO.
Paras Healthcare IPO Subscription Status , What to Track from October 21
As of October 16, 2026, subscription has not opened. The issue opens October 21. This section describes what to monitor during the three-day window.
At 75% QIB allocation, institutional demand drives this IPO more than any other investor category. A QIB book above 1x by Day 1 EOD confirms institutional confidence in the turnaround thesis. Below 0.5x at Day 2 EOD is a meaningful caution flag given that 75% of the issue depends on that category filling. NII (HNI) demand at 15% allocation usually responds strongly to healthcare sector IPOs with turnaround narratives. Track the NII figures alongside GMP movement for directional confirmation.
The retail category at 10% allocation is the tightest segment. At this quota level, even a 5x retail oversubscription translates to approximately 1-in-5 lottery odds per PAN. Multiple eligible family members applying independently each receive a separate lottery entry, improving collective probability without increasing per-application exposure.
Live subscription status by category updates in real time on NSE and BSE during the subscription window from October 21 to October 23.
Six Practical Tips for Retail Investors Considering This IPO
These tips are specific to Paras Healthcare’s profile: one-year-old profitability, high leverage, 75% QIB allocation, only 10% retail quota, and a debt-repayment-heavy use of proceeds.
Read the Q1 FY2027 financials, not just FY2026. The turnaround story only becomes compelling when the Q1 FY2027 numbers are in view. A single quarter producing more PAT than the full preceding year signals operating leverage turning strongly positive. Investors evaluating only FY2026 will underestimate the trajectory.
Apply at the cut-off price (Rs 693). A last-minute price band revision invalidates fixed-price bids. Selecting cut-off keeps the application live at whatever final price is approved, removing that execution risk entirely.
Understand the 10% retail quota before setting allotment expectations. Allotment odds here are structurally tighter than in a standard 35% retail allocation mainboard issue. At even moderate oversubscription, the per-PAN probability is lower than it appears. Multiple family PANs improve the collective probability where eligible family members each hold independent demat accounts.
Watch QIB subscription on Day 1 and Day 2, because this IPO is institutionally driven. At 75% QIB allocation, retail participation should follow institutional conviction, not lead it. A strong Day 1 QIB close validates the grey market signal. Weak QIB numbers through Day 2 is a warning that deserves attention before Day 3.
Factor the debt repayment story into the post-listing thesis. The fresh issue reduces borrowings by Rs 375 crore. If interest costs fall meaningfully, FY2027 PAT expansion beyond the Q1 trajectory becomes the base case. This is exactly what the 37.72x post-IPO P/E is pricing in. Investors who do not factor this in will misread the valuation as optically expensive.
Verify allotment on October 26 at the MUFG Intime registrar portal. Use PAN or application number at MUFG Intime India. Confirmed allotment before October 28 lets investors set a clear listing-day plan before the first volatile minutes of trading begin.
For a structured framework on evaluating healthcare sector IPOs, read How to Analyse an IPO.
Frequently Asked Questions
Q1. What is the Paras Healthcare IPO date and price band? The Paras Healthcare IPO opens on October 21, 2026 and closes on October 23, 2026. The price band is Rs 660 to Rs 693 per share, with a face value of Rs 1. The minimum retail application is one lot of 21 shares at Rs 14,553. Listing is scheduled for October 28, 2026 on BSE and NSE.
Q2. What is the Paras Healthcare IPO GMP today, and what listing price does it imply? As of October 16, 2026, the Paras Healthcare IPO GMP today stands at Rs 95 per share. Added to the upper band of Rs 693, this implies an estimated listing price of Rs 788, a notional gain of 13.71%. This is pre-subscription-open GMP with only three sessions of grey market data, making it less settled than a GMP reading taken during active subscription days.
Q3. Did Paras Healthcare post profits before this IPO? The company posted net losses in FY2024 (Rs 15.33 crore) and FY2025 (Rs 57.98 crore). FY2026 was the first profitable year, with PAT of Rs 43.83 crore. Q1 FY2027 PAT of Rs 49.68 crore already exceeds the full FY2026 figure. Key financial risks include a debt-to-equity ratio of 3.53x and a profitability track record of only one year.
Q4. How can investors check the Paras Healthcare IPO allotment status? Allotment is scheduled for October 26, 2026. Investors can check status on the MUFG Intime India registrar portal at mufgintimeindia.com using their PAN or application number. NSE and BSE portals also carry finalised allotment data once published.
Q5. Why does this IPO give retail investors only 10% of the offer? Under SEBI regulations, issuers can allocate up to 75% of the net offer to QIBs, leaving 15% for NIIs and only 10% for retail individual investors. Paras Healthcare has used this structure, which is more common in growth-stage or institutionally driven offerings. Retail applicants should plan with the expectation of tighter allotment odds than in a standard mainboard IPO that reserves 35% for retail.
Three Things to Watch Before October 28
This offering carries a genuine turnaround story, a high-debt balance sheet, and a valuation that assumes the trajectory continues. Three actions matter between now and listing day. First, track the QIB subscription close on October 21 and 22, since 75% QIB allocation makes institutional demand the single most important variable in this issue. A strong QIB book by Day 2 EOD validates the GMP signal and the bull case simultaneously. Second, verify allotment on October 26 at the MUFG Intime registrar portal, so the listing-day decision comes from a confirmed position rather than a guess. Third, check the Q1 FY2027 financials in the RHP for the clearest available picture of where earnings are heading, because the post-IPO valuation only holds if the Q1 trajectory is the new normal and not a one-quarter spike.
Track live GMP data across the October IPO calendar at IPO GMP Today.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy, sell, or hold any securities. ipocontrol.in is not registered with SEBI as an investment advisor. Stock market investments carry risk. Please read the Red Herring Prospectus (RHP) and all related offer documents carefully before investing. Consult a SEBI-registered investment advisor before making any investment decision.